Keytruda is effective for cervical cancer

Keytruda (pembrolizumab) has shown improved survival rate in chemotherapy with or without bevacizumab in patients with chronic, metastatic or recurrent cervical cancer. Based on the phase 3 KEYNOTE-826 results, which were presented at the ESMO Congress of the European Society of Medical Oncology, there was proved that the product reduced the risk of death by 33% in chemotherapy with or without pembrolizumab added.

In the Keytruda group, median overall survival rate was 24.4 months compared to 16.5 months in the chemotherapy group. The median survival rate without much progression is 10.4 months and 8.2 months in the chemotherapy group and the Keytruda group. The benefits of pembrolizumab have been noticed in both the general population group and in patients with high PD-K1 levels. Merck is currently promoting the extensive clinical development program of Keytruda and several other investigational and approved drugs for the treatment of different gynecological tumors.

Source: endpts